A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors

NCT05108623 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Tumor, Solid

Interventions

DRUG: agenT-797
DRUG: Approved ICIs

Sponsor

MiNK Therapeutics